Factors associated with ovarian function recovery after chemotherapy for breast cancer: A systematic review and meta-Analysis

Human Reproduction

Volumn 31, Issue 12, 2016, Pages 2737-2749

  Silva, Cristina ^a,d   Caramelo, Olga ^b   Almeida Santos, Teresa ^b,c   Rama, Ana Cristina Ribeiro ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d Azinhaga de Santa Comba Celas ^*  (Portugal)

Author keywords

Antineoplastic agents; Breast cancer; Chemotherapy; Fertility; Fertility preservation; GnRH agonists; Ovarian function; Recovery factors

Indexed keywords

ANTHRACYCLINE; GONADORELIN AGONIST; MUELLERIAN INHIBITING FACTOR; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; DRUG EXPOSURE; EARLY CANCER; EMBASE; ENGLISH (LANGUAGE); FEMALE; FEMALE FERTILITY; FERTILITY PRESERVATION; FOLLOW UP; FRENCH (LANGUAGE); HUMAN; MEDLINE; MENSTRUATION; META ANALYSIS; OVARY FUNCTION; PORTUGUESE (LANGUAGE); PREMENOPAUSE; REVIEW; RISK ASSESSMENT; SPANISH (LANGUAGE); SYSTEMATIC REVIEW; AGE; BREAST TUMOR; CONVALESCENCE; DRUG EFFECTS; OVARY; PROCEDURES;

AGE FACTORS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; FERTILITY PRESERVATION; HUMANS; OVARY; RECOVERY OF FUNCTION;

EID: 85014449523     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dew224     Document Type: Review

References (37)

1. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009;91:694-697.
2. Ben-Aharon I, Shalgi R. What lies behind chemotherapy-induced ovarian toxicity? Reproduction 2012;14:153-163.
3. Berliere M, Dalenc F, Malingret N, Vindevogel A, Piette P, Roche H, Donnez J, Symann M, Kerger J, Machiels JP. Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer 2008;8:56.
4. Broer SL, Broekmans FJ, Laven JS, Fauser BC. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update 2014;20:688-701.
5. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ, Panel Members. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015;26:1533-1546.
6. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, Giordano M, Garrone O, Pronzato P, Bighin C et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: A randomized trial. JAMA 2011;306:269-276.
7. Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, Griesinger G, Kelsey TW, La Marca A, Lambalk C et al. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update 2014;20:370-385.
8. Elgindy EA, El-Haieg DO, Khorshid OM, Ismail EI, Abdelgawad M, Sallam HN, Abou-Setta AM. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: A randomized controlled trial. Obstet Gynecol 2013;121:78-86.
9. Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, Fischer D, Sommer HL, Conrad B, Ortmann O et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: The GBG 37 ZORO study J Clin Oncol 2011;29:2334-2341.
10. Hamy AS, Porcher R, Cuvier C, Giacchetti S, Schlageter MH, Coussieu C, Gronier H, Feugeas JP, Adoui N, Lacorte JM et al. Ovarian reserve in breast cancer: Assessment with anti-Müllerian hormone. Reprod Biomed Online 2014;29:573-580.
11. Hamre H, Kiserud CE, Ruud E, Thorsby PM, Fossa SD. Gonadal function and parenthood 20 years after treatment for childhood lymphoma: A cross-sectional study. Pediatr Blood Cancer 2012;59:271-277.
12. Hayden JA, Danielle A, Jennifer LC, Pierre C, Claire B Assessing bias in studies of prognostic factors Ann Intern Med 2013;158:280-286.
13. Henry NL, Xia R, Schott AF, McConnell D, Banerjee M, Hayes DF. Prediction of postchemotherapy ovarian function using markers of ovarian reserve. Oncologist 2014;19:68-74.
14. Hickey M, Peate M, Saunders CM, Friedlander M. Breast cancer in young women and its impact on reproductive function. Hum Reprod Update 2009;15:323-339.
15. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA et al. The Cochrane Collaborations tool for assessing risk of bias in randomised trials BMJ 2011;343:d5928.
16. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
17. Kasum M, Beketi?-Oreškovi? L, Peddi PF, Oreškovi? S, Johnson RH. Fertility after breast cancer treatment. Eur J Obstet Gynecol Reprod Biol 2014;173:13-18.
18. Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, Giordano M, Garrone O, Levaggi A, Poggio F et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-Term ovarian function, pregnancies, and disease-free survival: A randomized clinical trial. JAMA 2015;314:2632-2640.
19. Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HAJr, Peccatori FA, Costa M, Revelli A, Salvagno F, Gennari A. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med 2016;14:1.
20. Lee S, Kil WJ, Chun M, Jung YS, Kang SY, Kang SH, Oh YT. Chemotherapy-related amenorrhea in premenopausal women with breast cancer. Menopause 2009;16:98-103.
21. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K, American Society of Clinical Oncology. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2500-2510.
22. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-Analyses: The PRISMA statement. Ann Intern Med 2009;151:264-269, w64.
23. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy N Engl J Med 2015; 372:923-932.
24. Munhoz RR, Pereira AA, Sasse AD, Hoff PM, Traina TA, Hudis CA, Marques RJ. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: A systematic review and meta-Analysis. JAMA Oncol 2016;2:65-73.
25. Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012;30:533-538.
26. Narmadha MP, Malaikkal V, Rajendran NN. Assessment of chemotherapy induced amenorrhea (CIA) in hormone receptor positive premenopausal women with breast cancer. Res J Pharm Biol Chem Sci 2012;3:97-106.
27. Nelson SM. Biomarkers of ovarian response: current and future applications. Fertil Steril 2013;99:963-969.
28. Partridge AH, Ruddy KJ, Gelber S, Schapira L, Abusief M, Meyer M, Ginsburg E. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 2010;94:638-644.
29. Peccatori FA, Azim HAJr, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, Pentheroudakis G, ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24:160-170.
30. Pérez-Fidalgo JA, Roselló S, García-Garré E, Jordá E, Martín-Martorell P, Bermejo B, Chirivella I, Guzman C, Lluch A. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: The impact of addition of taxanes to anthracycline-based regimens. Breast Cancer Res Treat 2010;120:245-251.
31. Reh A, Oktem O, Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: A prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril 2008;90:1635-1639.
32. Shen YW, Zhang XM, Lv M, Chen L, Qin TJ, Wang F, Yang J, Liu PJ, Yang J. Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: A systematic review and meta-Analysis. Onco Targets Ther 2015;8:3349-3359.
33. Song G, Gao H, Yuan Z. Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial. Med Oncol 2013;30:667.
34. Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 2007;30:126-132.
35. van der Kaaij MA, Heutte N, Meijnders P, Abeilard-Lemoisson E, Spina M, Moser EC, Allgeier A, Meulemans B, Simons AH, Lugtenburg PJ et al. Premature ovarian failure and fertility in long-Term survivors of Hodgkins lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe dEtude des Lymphomes de lAdulte Cohort Study. J ClinOncol 2012;30:291-299.
36. Verrill M. Chemotherapy for early-stage breast cancer: A brief history. Br J Cancer 2009;101:S2-S5.
37. Vitek WS, Shayne M, Hoeger K, Han Y, Messing S, Fung C. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: A systematic review and meta-Analysis. Fertil Steril 2014;102:808-815.